Et al).Nonetheless, it's hard to induce biologicfree remission inEt al).Even so, it is actually challeng

Ity Nijmegen Medical Centre, Geert Grooteplein 28, Nijmegen, 6525 GA, The Netherlands Full list of author information is available at the end of the articleof breast cancers. Apart from breast epithelial tumor cells, ESR2 is also expressed in adjacent infiltrating lymphocytes, fibroblasts, and endothelial cells, all of which are known to influence tumor growth [3]. However, its precise role in bre

Et al).Having said that, it's hard to induce biologicfree remission inEt al).Even so, it's complicated t

Ator of nuclear receptors, we explored its prognostic value in relation to estrogen-receptor-a (ESR1) and -b (ESR2) and evaluated its predictive value for response to tamoxifen treatment. Methods: DC-SCRIPT mRNA levels were measured by real-time PCR in 1,505 primary invasive breast cancers and associated with outcome (disease-free survival (DFS), metastasis-free survival (MFS) and overall survival

Ce Council: Dutch guidelines for pharmacoeconomic research. Amstelveen: Ziekenfondsraad; 1999.doi:10.1186/1471-2261-14-1 Cite this article as: van Riet et al.: Strategy to recognize and initiate treatment of chronic heart failure in primary care (STRETCH): a cluster randomized trial. BMC Cardiovascular Disorders 2014 14:1.Submit your next manuscript to BioMed Central and take full advantage of:?Co

Most likely these discrepant benefits are resulting from the studies beingProbably these discrepant bene

Either ESR1-positive and/or ESR2-low pT1 tumors.Introduction Estrogens influence the aggressiveness of breast cancer through their cognate nuclear receptors. In particular, the estrogen receptor-alpha (ERa) (ESR1) - present in tumor cells of about 70 to 75 of all breast tumors is considered crucial because of its proliferationinducing actions and for that reason is an important target for therap

Either ESR1-positive and/or ESR2-low pT1 tumors.Introduction Estrogens influence the aggressiveness of breast cancer through their cognate nuclear receptors. In particular, the estrogen receptor-alpha (ERa) (ESR1) - present in tumor cells of about 70 to 75 of all breast tumors is considered crucial because of its proliferationinducing actions and for that reason is an important target for therap